Telix Pharmaceuticals Limited (TLPPF)
USD 17.87
(3.8%)
USD 17.87
(3.8%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -105.79 Million AUD | 0.09% |
| 2022 | -105.88 Million AUD | -443.05% |
| 2021 | -19.49 Million AUD | 74.26% |
| 2020 | -75.73 Million AUD | -78.35% |
| 2019 | -42.46 Million AUD | -76.64% |
| 2018 | -24.04 Million AUD | 50.34% |
| 2017 | -48.41 Million AUD | 0.0% |
| 2000 | -2.99 Million AUD | 0.0% |
| 1999 | - AUD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -103.62 Million AUD | 36.13% |
| 2024 Q2 | -106.98 Million AUD | -43.09% |
| 2023 Q4 | -105.79 Million AUD | 0.56% |
| 2023 Q1 | 129.01 Million AUD | 221.85% |
| 2023 Q2 | -118.62 Million AUD | -191.94% |
| 2023 Q3 | -106.38 Million AUD | 10.32% |
| 2023 FY | -105.79 Million AUD | 0.09% |
| 2022 Q4 | -105.88 Million AUD | 0.6% |
| 2022 Q2 | -120.04 Million AUD | 0.46% |
| 2022 Q3 | -106.52 Million AUD | 11.26% |
| 2022 Q1 | -120.59 Million AUD | -518.51% |
| 2022 FY | -105.88 Million AUD | -443.05% |
| 2021 Q3 | -20.11 Million AUD | 58.03% |
| 2021 Q4 | -19.49 Million AUD | 3.05% |
| 2021 Q2 | -47.91 Million AUD | 1.05% |
| 2021 Q1 | -48.42 Million AUD | 36.06% |
| 2021 FY | -19.49 Million AUD | 74.26% |
| 2020 Q3 | -76.24 Million AUD | -257.89% |
| 2020 Q1 | -22.78 Million AUD | 46.34% |
| 2020 Q4 | -75.73 Million AUD | 0.66% |
| 2020 FY | -75.73 Million AUD | -78.35% |
| 2020 Q2 | -21.3 Million AUD | 6.51% |
| 2019 FY | -42.46 Million AUD | -76.64% |
| 2019 Q1 | -8.44 Million AUD | 64.89% |
| 2019 Q2 | -8.34 Million AUD | 1.18% |
| 2019 Q4 | -42.46 Million AUD | 0.05% |
| 2019 Q3 | -42.48 Million AUD | -409.4% |
| 2018 Q1 | -26.01 Million AUD | 46.28% |
| 2018 FY | -24.04 Million AUD | 50.34% |
| 2018 Q4 | -24.04 Million AUD | 0.0% |
| 2018 Q3 | -24.04 Million AUD | 7.57% |
| 2018 Q2 | -26.01 Million AUD | 0.0% |
| 2017 FY | -48.41 Million AUD | 0.0% |
| 2017 Q2 | -5.9 Million AUD | 0.0% |
| 2017 Q3 | -48.41 Million AUD | -720.29% |
| 2017 Q4 | -48.41 Million AUD | 0.0% |
| 2017 Q1 | -5.9 Million AUD | 0.0% |
| 2000 FY | -2.99 Million AUD | 0.0% |
| 1999 FY | - AUD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Bioxytran, Inc. | 1.89 Million USD | 5671.184% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 771.141% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 26426.307% |
| SQZ Biotechnologies Company | -36.23 Million USD | -191.937% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 4818.154% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 347.218% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | -1578.033% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | 11510.008% |
| Marizyme, Inc. | 18.56 Million USD | 669.723% |
| Genus plc | 190.6 Million USD | 155.505% |
| Pharming Group N.V. | 109.8 Million USD | 196.346% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | 12397.949% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | 8815.137% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | 15657.647% |
| ContraFect Corporation | -6.02 Million USD | -1655.592% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | 9256.08% |
| IMV Inc. | 7.67 Million USD | 1479.202% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 2022.828% |
| ONE Bio Corp. | 9.04 Million USD | 1270.261% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 917.179% |
| Mesoblast Limited | 55.85 Million USD | 289.394% |
| MultiCell Technologies, Inc. | 90.04 USD | 117494546.912% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 446.246% |
| Genscript Biotech Corporation | -1.06 Billion USD | 90.032% |
| Neon Bloom, Inc. | 622.36 Thousand USD | 17098.413% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | 10598.196% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 2668.999% |
| Biomind Labs Inc. | 711.4 Thousand USD | 14970.917% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | 5391.209% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 926.075% |
| Skye Bioscience, Inc. | -5.72 Million USD | -1749.061% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 29510.358% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | 4831.661% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | 75771.655% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | 78674.559% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 1972.965% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | 532601.133% |
| Accustem Sciences Inc. | -733.97 Thousand USD | -14313.511% |
| EV Biologics, Inc. | 1.36 Million USD | 7833.497% |
| Q BioMed Inc. | 4.06 Million USD | 2705.709% |
| GB Sciences, Inc. | 1.74 Million USD | 6154.543% |
| Alpha Cognition Inc. | -183.78 Thousand USD | -57461.974% |
| CSL Limited | 10.52 Billion USD | 101.005% |
| Agentix Corp. | 37.63 Thousand USD | 281229.919% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 274.731% |
| Enzolytics Inc. | 981.65 Thousand USD | 10876.891% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Resverlogix Corp. | 6.45 Million USD | 1739.932% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | -15617.387% |
| MetaStat, Inc. | - USD | Infinity% |
| Curative Biotechnology, Inc. | 2.2 Million USD | 4904.401% |
| argenx SE | -2.02 Billion USD | 94.786% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 343.57% |
| HST Global, Inc. | 96.79 Thousand USD | 109397.16% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | -125.032% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | 51401.299% |
| Halberd Corporation | 144.72 Thousand USD | 73200.656% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 1596.145% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | -1096.754% |
| Zenith Capital Corp. | 10.06 Thousand USD | 1051292.369% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 4005.76% |
| GeneThera, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 4533.801% |
| AVAX Technologies, Inc. | -5.9 Million USD | -1692.111% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | 64407.728% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | -577430.298% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | 52881.991% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Adynxx, Inc. | - USD | Infinity% |
| NovAccess Global Inc. | 2.17 Million USD | 4956.263% |
| Helix BioMedix, Inc. | -2.57 Million USD | -4016.369% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 621.76% |
| Kadimastem Ltd | -253.1 Thousand USD | -41698.168% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| BioStem Technologies, Inc. | 4.47 Million USD | 2465.647% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | 52666.409% |
| Burzynski Research Institute, Inc. | -1310.00 USD | -8075625.191% |
| LadRx Corporation | -2.03 Million USD | -5094.874% |
| Cell Source, Inc. | 9.23 Million USD | 1245.931% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | -518284.947% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 16755.777% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 16755.777% |
| Affymax, Inc. | -5.59 Million USD | -1790.155% |
| Mobile Lads Corp. | 484.23 Thousand USD | 21947.379% |
| Itoco Inc. | 228.3 Thousand USD | 46438.013% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | 77894.527% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 2234.194% |
| International Stem Cell Corporation | 2.59 Million USD | 4184.633% |
| CytoDyn Inc. | 20.26 Million USD | 622.12% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | -16351059.196% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | -1141334.173% |
| Qrons Inc. | 351.42 Thousand USD | 30203.549% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 1472.852% |
| SYBLEU INC | 473.71 Thousand USD | 22432.462% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | -42281.219% |
| Rebus Holdings, Inc. | 305 Thousand USD | 34785.902% |
| GlobeImmune, Inc. | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 2473.603% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | 169603.148% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 4950.841% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 3180.722% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 1336.899% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | 772.6 Thousand USD | 13792.861% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | -8363.36% |
| Neutra Corp. | 52.18 Thousand USD | 202817.152% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | -4150.382% |
| PureTech Health plc | -167.19 Million USD | 36.726% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | -43096.629% |
| IXICO plc | -4.44 Million USD | -2280.244% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 900.303% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 292.872% |
| CSL Limited | 10.52 Billion USD | 101.005% |
| Cellectis S.A. | -43.81 Million USD | -141.43% |